Preferentially Expressed Antigen in Melanoma (PRAME) Peptide
PRAME
Reactivité: Mammifères
Hôte: Synthetic
BP, WB, IHC
-
- Antigène Tous les produits PRAME
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
- Type de proteíne
- Synthetic
- Origine
- Mammifères
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Séquence
- AMVQAWPFTC LPLGVLMKGQ HLHLETFKAV LDGLDVLLAQ EVRPRRWKLQ
- Attributs du produit
-
A synthetic peptide for use as a blocking control in assays to test for specificity of PRAME antibody,
Alternative Names: PRAME control peptide, PRAME antibody Blocking Peptide, Anti-PRAME Blocking Peptide, Preferentially Expressed Antigen In Melanoma Blocking Peptide, MAPE Blocking Peptide, OIP4 Blocking Peptide
-
-
- Indications d'application
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Conseil sur la manipulation
- Avoid repeated freeze/thaw cycles.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20 °C long term.
-
- Antigène
- PRAME (Preferentially Expressed Antigen in Melanoma (PRAME))
- Synonymes
- PRAME Peptide, CT130 Peptide, MAPE Peptide, OIP-4 Peptide, OIP4 Peptide, 4930534P07Rik Peptide, preferentially expressed antigen in melanoma Peptide, PRAME Peptide, Prame Peptide
- Sujet
- PRAME functions as a transcriptional repressor, inhibiting the signaling of retinoic acid through the retinoic acid receptors RARA, RARB and RARG. PRAME prevents retinoic acid-induced cell proliferation arrest, differentiation and apoptosis.
- Poids moléculaire
- 56 kDa
-
Vous êtes ici:
